AR015485A1 - A TRAGABLE ORAL CAPSULE CONTAINING PAROXETINE, A SOLID FORMAT ORIGINABLE DOSE DOSAGE, A PHARMACEUTICAL FORMULATION, A PARAPREPARATION PROCEDURE OF THIS FORMULATION AND THE USE OF DISSOLVED PAROXETINE IN A VEHICLE TO MANUFACTURE TWO ORIGINAL FORMULATION - Google Patents
A TRAGABLE ORAL CAPSULE CONTAINING PAROXETINE, A SOLID FORMAT ORIGINABLE DOSE DOSAGE, A PHARMACEUTICAL FORMULATION, A PARAPREPARATION PROCEDURE OF THIS FORMULATION AND THE USE OF DISSOLVED PAROXETINE IN A VEHICLE TO MANUFACTURE TWO ORIGINAL FORMULATIONInfo
- Publication number
- AR015485A1 AR015485A1 ARP980105880A ARP980105880A AR015485A1 AR 015485 A1 AR015485 A1 AR 015485A1 AR P980105880 A ARP980105880 A AR P980105880A AR P980105880 A ARP980105880 A AR P980105880A AR 015485 A1 AR015485 A1 AR 015485A1
- Authority
- AR
- Argentina
- Prior art keywords
- paroxetine
- formulation
- solid
- vehicle
- dissolved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Una cápsula oral tragable y una forma solida de dosificacion oral tragable de paroxetina en las que la paroxetina está en disolucion en un vehículosolido, semisolido o líquido. Las disoluciones se utilizan para rellenar cápsulas, o si se trata de disoluciones solidas auto-soportantes se moldean en formassolidas de dosificacion tales como tabletas o perlas. También se describen nuevas formulaciones líquidas en las que se utiliza un agente solubilizantepra solubilizar paroxetina en aceites y/o lípidos, para evitar otras formas de paroxetina que se convierten en el hemihidrato, por utilizacion de vehículoso excipientes anhidros o hidrofobos. Además se describe un procedimiento para preparar dicha formulacion y la utilizacion de paroxetina disuelta en unvehículo para fabricar cápsulas o formas solidas de dosificacion orales tragables para el tratamiento y/o profilaxis de uno o más trastornos.A swallowed oral capsule and a solid swallowable oral dosage form of paroxetine in which paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or in the case of solid self-supporting solutions they are molded into solid dosage forms such as tablets or beads. New liquid formulations are also described in which a solubilizing agent is used to solubilize paroxetine in oils and / or lipids, to avoid other forms of paroxetine that are converted into the hemihydrate, by use of vehicles or anhydrous or hydrophobic excipients. In addition, a method for preparing said formulation and the use of paroxetine dissolved in a vehicle for manufacturing capsules or oral swallowable solid dosage forms for the treatment and / or prophylaxis of one or more disorders is described.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9724544.3A GB9724544D0 (en) | 1997-11-21 | 1997-11-21 | Novel Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015485A1 true AR015485A1 (en) | 2001-05-02 |
Family
ID=10822374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105880A AR015485A1 (en) | 1997-11-21 | 1998-11-19 | A TRAGABLE ORAL CAPSULE CONTAINING PAROXETINE, A SOLID FORMAT ORIGINABLE DOSE DOSAGE, A PHARMACEUTICAL FORMULATION, A PARAPREPARATION PROCEDURE OF THIS FORMULATION AND THE USE OF DISSOLVED PAROXETINE IN A VEHICLE TO MANUFACTURE TWO ORIGINAL FORMULATION |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1033986A1 (en) |
| JP (1) | JP2001523718A (en) |
| KR (1) | KR20010032320A (en) |
| CN (1) | CN1279608A (en) |
| AP (1) | AP2000001821A0 (en) |
| AR (1) | AR015485A1 (en) |
| AU (1) | AU1168099A (en) |
| BG (1) | BG104527A (en) |
| BR (1) | BR9814220A (en) |
| CO (1) | CO4970832A1 (en) |
| DZ (1) | DZ2658A1 (en) |
| EA (1) | EA200000552A1 (en) |
| GB (1) | GB9724544D0 (en) |
| HU (1) | HUP0100580A3 (en) |
| IL (1) | IL136106A0 (en) |
| MA (1) | MA24704A1 (en) |
| NO (1) | NO20002590L (en) |
| OA (1) | OA11385A (en) |
| PE (1) | PE20000381A1 (en) |
| PL (1) | PL340555A1 (en) |
| SK (1) | SK7342000A3 (en) |
| TR (1) | TR200001423T2 (en) |
| WO (1) | WO1999026625A1 (en) |
| ZA (1) | ZA9810637B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810180D0 (en) * | 1998-05-13 | 1998-07-08 | Smithkline Beecham Plc | Novel formulation |
| EP1161241B1 (en) * | 1999-03-12 | 2005-12-07 | Aesica Pharmaceuticals Ltd. | Stable pharmaceutical application form for paroxetin anhydrate |
| ATE248165T1 (en) | 1999-07-01 | 2003-09-15 | Italfarmaco Spa | COMPLEXES OF PAROXETINE WITH CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVES |
| DE19930454A1 (en) * | 1999-07-02 | 2001-01-04 | Knoll Ag | Solid paroxetine-containing preparations |
| US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| DE60222803T2 (en) * | 2001-12-21 | 2008-07-17 | Supernus Pharmaceuticals, Inc. | ORAL CAPSULE FORMULATION WITH IMPROVED PHYSICAL STABILITY |
| SE0200475D0 (en) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral pharmaceutical preparation |
| WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
| WO2011071194A1 (en) * | 2009-12-08 | 2011-06-16 | 주식회사 일화 | SOLID DISPERSIONS CONTAINING 20-O-β-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CN103961333B (en) * | 2014-05-07 | 2020-02-21 | 浙江华海药业股份有限公司 | Paroxetine mesylate capsule and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216934A1 (en) * | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
| KR20000070151A (en) * | 1997-01-15 | 2000-11-25 | 피터 기딩스 | Paroxetine Compositions |
-
1997
- 1997-11-21 GB GBGB9724544.3A patent/GB9724544D0/en not_active Ceased
-
1998
- 1998-11-18 TR TR2000/01423T patent/TR200001423T2/en unknown
- 1998-11-18 CN CN98811404A patent/CN1279608A/en active Pending
- 1998-11-18 DZ DZ980268A patent/DZ2658A1/en active
- 1998-11-18 WO PCT/GB1998/003471 patent/WO1999026625A1/en not_active Application Discontinuation
- 1998-11-18 AU AU11680/99A patent/AU1168099A/en not_active Abandoned
- 1998-11-18 AP APAP/P/2000/001821A patent/AP2000001821A0/en unknown
- 1998-11-18 PE PE1998001126A patent/PE20000381A1/en not_active Application Discontinuation
- 1998-11-18 PL PL98340555A patent/PL340555A1/en unknown
- 1998-11-18 KR KR1020007005532A patent/KR20010032320A/en not_active Application Discontinuation
- 1998-11-18 JP JP2000521827A patent/JP2001523718A/en active Pending
- 1998-11-18 BR BR9814220-8A patent/BR9814220A/en not_active Application Discontinuation
- 1998-11-18 SK SK734-2000A patent/SK7342000A3/en unknown
- 1998-11-18 IL IL13610698A patent/IL136106A0/en unknown
- 1998-11-18 HU HU0100580A patent/HUP0100580A3/en unknown
- 1998-11-18 EA EA200000552A patent/EA200000552A1/en unknown
- 1998-11-18 EP EP98954631A patent/EP1033986A1/en not_active Withdrawn
- 1998-11-19 MA MA25357A patent/MA24704A1/en unknown
- 1998-11-19 AR ARP980105880A patent/AR015485A1/en unknown
- 1998-11-20 ZA ZA9810637A patent/ZA9810637B/en unknown
- 1998-11-20 CO CO98068459A patent/CO4970832A1/en unknown
-
2000
- 2000-05-19 NO NO20002590A patent/NO20002590L/en not_active Application Discontinuation
- 2000-05-19 OA OA1200000153A patent/OA11385A/en unknown
- 2000-06-13 BG BG104527A patent/BG104527A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DZ2658A1 (en) | 2003-03-22 |
| BG104527A (en) | 2001-04-30 |
| HUP0100580A3 (en) | 2002-05-28 |
| EP1033986A1 (en) | 2000-09-13 |
| ZA9810637B (en) | 2000-05-22 |
| CN1279608A (en) | 2001-01-10 |
| WO1999026625A1 (en) | 1999-06-03 |
| KR20010032320A (en) | 2001-04-16 |
| TR200001423T2 (en) | 2000-10-23 |
| NO20002590L (en) | 2000-07-19 |
| EA200000552A1 (en) | 2000-10-30 |
| IL136106A0 (en) | 2001-05-20 |
| AP2000001821A0 (en) | 2000-06-30 |
| MA24704A1 (en) | 1999-07-01 |
| CO4970832A1 (en) | 2000-11-07 |
| SK7342000A3 (en) | 2000-12-11 |
| JP2001523718A (en) | 2001-11-27 |
| NO20002590D0 (en) | 2000-05-19 |
| AU1168099A (en) | 1999-06-15 |
| BR9814220A (en) | 2001-12-26 |
| HUP0100580A2 (en) | 2002-04-29 |
| GB9724544D0 (en) | 1998-01-21 |
| OA11385A (en) | 2004-01-27 |
| PL340555A1 (en) | 2001-02-12 |
| PE20000381A1 (en) | 2000-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7501926B2 (en) | Controlled release dosage forms for specific gastrointestinal sites | |
| AR015485A1 (en) | A TRAGABLE ORAL CAPSULE CONTAINING PAROXETINE, A SOLID FORMAT ORIGINABLE DOSE DOSAGE, A PHARMACEUTICAL FORMULATION, A PARAPREPARATION PROCEDURE OF THIS FORMULATION AND THE USE OF DISSOLVED PAROXETINE IN A VEHICLE TO MANUFACTURE TWO ORIGINAL FORMULATION | |
| ES2593047T3 (en) | Treatment of vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | |
| US20030104048A1 (en) | Pharmaceutical dosage forms for highly hydrophilic materials | |
| BR9916224A (en) | Oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form, for the treatment and prophylaxis of gastrointestinal disorders and to prevent gastrointestinal side effects, use of a dosage form, combination, and ampoule packaging | |
| ES2164940T3 (en) | BIOADHESIVE SOLID DOSAGE FORM. | |
| AR006652A1 (en) | PHARMACEUTICAL FORM OF ORAL DOSAGE FOR THE ORAL TREATMENT OF BONE DISEASES. | |
| RU2012102772A (en) | PHARMACEUTICAL TABLET CONTAINING A FILLED FILLED CAPSULE | |
| ES2187822T3 (en) | FAST DISGREGATION TABLETS. | |
| CO4940409A1 (en) | COVERED TABLET WITH FILM FOR IMPROVED SAFETY OF THE UPPER GASTROINTESTINAL TRACT | |
| JP7261830B2 (en) | Dosage Forms and Their Use | |
| ECSP034826A (en) | METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE | |
| CN105142596A (en) | Compositions for treatment of xerostomia and for tooth treatment | |
| Cocoș et al. | Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity | |
| BR0210224A (en) | Dosage forms designed to be swallowed directly and presented as a swallowable tablet or capsule formulation and process for preparing a dosage form | |
| MXPA06008241A (en) | Dermatologic soft gel compositions. | |
| BR0115989A (en) | A pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient. | |
| JPH02157220A (en) | Sustained-relies suppository | |
| AR013261A1 (en) | PHARMACEUTICAL FORMULATIONS FOR CAMPTOTECINE ANALOGS IN A GELATIN CAPSULE | |
| HUT62471A (en) | Process for producing pharmaceutical compositions comprising ipriflavone | |
| ES2935528T3 (en) | Formulation and oral suspension of an oncological drug | |
| ES2286998T3 (en) | STABLE FORMULATION CONTAINING FUMAGILLINA. | |
| DE60331920D1 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR SOAP CAPSULES WITH VINORELBIN AND TREATMENT PROCEDURES | |
| AR033331A1 (en) | POLYMORPH FORMS OF A AZABICICLO CITRATE [2,2,2] OCTAN-3-AMINA, ITS PHARMACEUTICAL COMPOSITIONS, PROCESSING PROCEDURE AND PROCEDURE FOR PRODUCTION. | |
| HN1999000174A (en) | ACUISA MEDICATION FORMULATION FOR ORAL ADMINISTRATION. |